Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 14/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303273 | 1.00 | CMA1 (0.40) | CMA1KMT2AMEN1ELANEXIAP | |
| SCHEMBL12303272 | 0.93 | BIRC2 (0.41) | CMA1KMT2AMEN1ELANEXIAP | |
| SCHEMBL2579341 | 0.93 | BIRC2 (0.41) | CMA1KMT2AMEN1ELANEXIAP | |
| SCHEMBL15139234 | 0.89 | HTR6 (0.40) | XIAPBIRC3BIRC2 | |
| SCHEMBL16501392 | 0.89 | HTR6 (0.40) | XIAPBIRC3BIRC2 | |
| SCHEMBL12529610 | 0.88 | CMA1 (0.43) | CMA1KMT2AMEN1ELANECTRC | |
| SCHEMBL12529600 | 0.87 | CMA1 (0.42) | CMA1KMT2AMEN1ELANEXIAP | |
| SCHEMBL4245182 | 0.82 | CMA1 (0.35) | CMA1 | |
| SCHEMBL1749822 | 0.81 | CMA1 (0.45) | CMA1ELANECTRC | |
| SCHEMBL12529525 | 0.80 | CMA1 (0.43) | CMA1KMT2AMEN1ELANEXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851200-B1 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20110301151-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORPORATION | 2011-12-08 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | CMA1 2903/4885KMT2A 1933/4885MEN1 900/4885 |
| US-20110301151-A1 | DIMERIC IAP INHIBITORS | BIRC2, XIAP, BIRC5 | CMA1 3492/4885KMT2A 3763/4885MEN1 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.